Match Document Document Title
9040667 Antibody cocktail  
The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to...
9040043 Monoclonal antibodies against GMF-B antigens, and uses therefor  
The disclosure relates to anti-glial maturation factor beta (“GMF-B”) monoclonal antibodies (mAbs) and fragments thereof, as well as hybridoma lines that secrete antibodies or fragments....
9040666 Single-domain antigen-binding proteins that bind mammalian IgG  
The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably...
9040310 Antibody-nanoparticle conjugates and methods for making and using such conjugates  
Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more...
9040042 Optimized antibodies that target HM1.24  
The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent...
9035026 Anti-CD16 binding molecules  
The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and...
9034324 Anti-BCMA antibodies  
This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for...
9034819 Method of lowering cholesterol and triglycerides by administering exendins  
Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained...
9029510 Fully human antibodies that bind to VEGFR2 and methods of use thereof  
There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and...
9029515 Anti-PCSK9 antibodies with pH dependent antigen binding  
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH...
9029509 Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)  
The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the...
9029508 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
9029513 Anti-EGFR antibody and use thereof  
A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope...
9029511 Compositions and methods for the diagnosis and treatment of tumor  
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
9028826 Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties  
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune...
9023995 Anti IL-36R antibodies  
The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using...
9023993 Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient  
A monoclonal antibody having a neutralizing activity on HB-EGF is disclosed. The monoclonal antibody of the present invention is preferably an antibody that does not bind to the HB-EGF protein on...
9023994 Immunoglobulin reduced in thrombogenic agents and preparation thereof  
The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a...
9023353 Anti-(+)—methamphetamine monoclonal antibodies  
The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into...
9017670 Anti-Tie2 antibodies and uses thereof  
The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to...
9018357 Anti-VEGF antibodies  
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries...
9018163 Modulating PDX-1 with PCIF1, methods and uses thereof  
This invention relates to PCIFl and its use as a target for the improvement of pancreatic islet β cell mass and function in diabetes. Specifically, the invention relates to the use of compounds...
9018356 Anti-ANGPTL3 antibodies and uses thereof  
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3)...
9018305 Chromatography matrices including novel Staphylococcus aureus protein a based ligands  
The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well...
9017684 Diagnosis and treatment of cancer using anti-EREG antibody  
Methods that entail detection of an epiregulin (EREG) protein for cancer diagnosis are disclosed. In colon cancer, lung adenocarcinoma, pancreatic cancer, stomach cancer, and kidney cancer, the...
9017669 Anti-CDH3 antibodies and uses thereof  
The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an...
9011847 Anti-FAP antibodies and methods of use  
The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
9011862 Inhibitors of the nitration of amyloid β peptides and their uses in the diagnosis and treatment of Alzheimer's disease  
The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-β peptide (Aβ), comprising the steps of a) contacting at least one Aβ -peptide and/or the...
9012607 Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II  
Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
9011856 Antibodies specific for sclerostin and methods for increasing bone mineralization  
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by...
9011858 Variable region sequences of IL-31 monoclonal antibodies and methods of use  
Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules...
9011854 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Anti-DLL3 antibody drug conjugates and methods of use
 
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
9005926 Methods of preventing and removing trisulfide bonds  
The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide...
9005612 Binding domain-immunoglobulin fusion proteins  
The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region...
9005356 Tropoelastin for promoting endothelial cell adhesion or migration  
The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.
9005615 Methods for treatment of inflammatory diseases  
The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment...
9005620 Compounds  
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating...
9006400 Fibroblast growth factor-21-Fc fusion proteins  
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also...
9005613 Anti-mucin antibodies for early detection and treatment of pancreatic cancer  
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show...
9006396 CsPCNA isoform antibodies and uses thereof  
Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods...
9005963 Amino acid sequences directed against cellular receptors for viruses and bacteria  
The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically...
8999331 Immunobinders directed against sclerostin  
Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for...
9000127 Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)  
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such...
8999327 Antibodies against human CSF-1R and uses thereof  
The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
9000128 Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof  
The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such...
9000129 Anti-GCC antibody molecules and methods for use of same  
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding...
9000131 Antibodies that neutralize botulinum neurotoxins  
This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The...
8999931 Pharmaceutical composition using gonadotropin-releasing hormone (GNRH) combined variants as immunogen  
A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule;...
8992910 IL3Rα antibody conjugates and uses thereof  
The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for...
8992913 Antagonist antibodies against GDF-8 and uses therefor  
The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are...